BiolineRX Gains Momentum for Pre-Clinical HCV Drug
March 15, 2013
BiolineRX in advanced talks on hepatitis C drug development deal
BL-8030 is an orally-available small molecule to suppress the substance thought critical for the replication of the hepatitis virus.
12 March 13, Gali Wienreb
BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) today announced in its financial report for 2012 that it is advanced talks on a joint development agreement for BL-8030 for the treatment of hepatitis C, which could substantially expedite the development process.
Analysis of the remarks by BiolineRX CEO Dr. Kinneret Savitsky implies that the deal is not yet a material commercialization agreement, but an earlier stage deal involving joint investment in development of the drug. Nonetheless, this is an interesting development for the product, which is still in the preclinical stage. There have been other development collaboration agreements signed for hepatitis C drugs in the preclinical stage.
Continue reading this entire article:
New Strategy Shifts Pfizer Away from New Hep C Drug
Upcoming Hepatitis C Trial